Sermorlin Acetate / 99% Purity/ 10mg SMO10/ Growth-promoting peptide
2 Inquiries
114466-38-5
Pharmaceutical Grade
99%
HongKong
HUATAI
10 vials/kit
2026-09-04
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
Sermorelin Acetate
CAS No.:114466-38-5
Molecular Formula:C149H246N44O42S
InChIKeys:BVLCEKWPOSAKSZ-YQMCHIOTSA-N
Molecular Weight:3417.9 g/mol
Exact Mass:3416.843184 g/mol
Categories:
Characteristics-
PSA:
1510 Ų
XLogP3:5.07090
Research-
Class:
GHRH analog (1–29 amino-terminal fragment, 29-amino-acid peptide amide)
Status:FDA-approved diagnostic agent (Geref, discontinued). NOT for therapeutic use.
Mechanism:A synthetic 29-amino-acid peptide (H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂) identical to the amino-terminal segment of endogenous human GHRH. Sermorelin binds to the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, stimulating pulsatile GH synthesis and secretion via the cAMP/PKA pathway. Unlike exogenous GH, sermorelin preserves the endogenous GH pulsatility and IGF-1 feedback loop.
EC50 (Ghrhr Ec50):~0.1–1 nM (cAMP accumulation in rat pituitary cells)
Source:DrugBank: DB00010. Frohman LA, et al. Endocr Rev. 1986;7(3):223–253.DOI
Clinical Development:FDA:Geref (approved 1991-10-11)
References-
ChEMBL:
CHEMBL1201555
DrugBank:KEGG DRUG:D08554
PubChem:Literature:Disclaimer:Sermorelin was FDA-approved as a diagnostic agent (Geref) for growth hormone deficiency but has been discontinued (not for safety reasons). It is NOT approved for anti-aging, bodybuilding, or therapeutic GH replacement. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Sermorelin acetate HGRH
1 KG Nov 25, 2025 
South Korea
Sermorlin Acetate
10 Jul 25, 2025 Post an enquiry for this product
